A series of bornyl derivatives of p-(benzyloxy)phenylpropionic
acid were prepared, and their
hypoglycemic activities were examined by an oral
glucose tolerance test in mice. The results of this test revealed two compounds, 1 and 3, that can reduce the blood level of
glucose similarly to reference compound
vildagliptin. Both compounds were tested in an experiment on mice with metabolic disorders: the C57BL/6Ay strain. Along with
hypoglycemic properties, the two compounds showed different abilities to correct
lipid metabolism disorders. In silico prediction revealed that the studied substances are most likely bifunctional multitarget
hypoglycemic compounds whose mechanism of action is based on a pronounced reduction in
insulin resistance and a strong
incretin-mimetic effect. The difference in the size of effects of these compounds on biochemical parameters of blood in the experiment on C57BL/6Ay mice was in good agreement with the computational prediction of the priority ranking of biological targets for these compounds. These results indicate that bornyl derivatives of p-(benzyloxy)phenylpropionic
acid have a good potential as new agents for
diabetes mellitus treatment due to their
hypoglycemic and
lipid-normalizing properties.